Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT03221738 Completed - Clinical trials for Body Dysmorphic Disorders

Smartphone-Administered App Treatment for Adults With Body Dysmorphic Disorder

Start date: July 24, 2017
Phase: N/A
Study type: Interventional

The investigators are developing and testing a Smartphone-based cognitive behavioral therapy (CBT) "app" for body dysmorphic disorder (BDD). The investigators hypothesize that app-based CBT for BDD will be feasible and acceptable to individuals with BDD, and will improve body image concerns and related outcomes.

NCT ID: NCT03217123 Completed - Clinical trials for Obsessive-Compulsive Disorder

Deep-brain Stimulation in Obsessive-compulsive Disorder: Randomized, Double-blinded Clinical Trial

10/131
Start date: January 1, 2011
Phase: N/A
Study type: Interventional

A prospective, randomized, double-blinded study was conducted in 7 OCD patients during which 4 electrode contacts along a striatal axis were stimulated bilaterally. DBS electrode implantation followed a trajectory placing contact zero in nucleus accumbens (a common target for OCD treatment) with more proximal contacts placed in striatal segments defined using projections from prefrontal cortex subdivisions (ventromedial, orbitofrontal, dorsolateral) and anterior cingulate cortex.

NCT ID: NCT03209258 Completed - Stroke Clinical Trials

The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial

INTERACT3
Start date: December 12, 2017
Phase: N/A
Study type: Interventional

Continued uncertainty exists over benefits of early intensive blood pressure (BP) lowering in acute intracerebral hemorrhage (ICH), related to the non-significant primary outcomes, patient selection, and discordant results of INTERACT2 and ATACH-II. We designed INTERACT3 to determine the effectiveness of a goal-directed care bundle of active management (intensive BP lowering, glycemic control, treatment of pyrexia and reversal of anticoagulation) vs. usual care in ICH. INTERACT3 is a large-scale pragmatic clinical trial to provide reliable evidence over the effectiveness of a widely applicable goal-directed care bundle in acute ICH.

NCT ID: NCT03208036 Completed - Schizophrenia Clinical Trials

Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness

Start date: July 15, 2018
Phase: N/A
Study type: Interventional

Development of interventions that can effectively target and remediate the cognitive and functional impairment associated with serious mental illness is a treatment priority. Transcranial direct current stimulation (tDCS) is a safe, non-invasive neuromodulation technique that is capable of stimulating brain activity to facilitate learning. The primary objective of this study is to evaluate the pairing of two therapeutic techniques, cognitive remediation and tDCS, as a cognitively enhancing intervention. This study is designed to test the hypotheses that cognitive remediation paired with tDCS will be more efficacious than cognitive remediation delivered with sham stimulation and that intervention-induced cognitive change will be sustainable. To examine the incremental benefit of pairing tDCS with cognitive remediation, clinically stable outpatients between the ages of 18-65 who have a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder will be enrolled in a double-blind, double-baseline, sham-controlled clinical trial. Participants will be randomized in a 1:1 ratio to receive either tDCS or sham stimulation concurrent with working memory focused cognitive remediation. Training will be offered to participants in a small group format. Training will consist of 48 sessions, with 2-3 sessions scheduled in a week. Each training session will last 2 hours. One hour will be spent completing cognitive exercises that require working memory skills on a computer. TDCS or sham stimulation will be offered concurrent with the first 20 minutes of training with a StarStim neuromodulator. One mA of anodal stimulation will be applied to the left dorsal lateral prefrontal cortex and the cathodal electrode will be placed in the contralateral supraorbital position. Upon completion of working memory training, participants will transition to a 45-minute bridging group focus on application of cognitive skills in everyday life. To assess intervention-induced change, working memory, other aspects of cognition, functional capacity, community functioning, and symptom severity will be assessed pre- and post-intervention. Sustainability of intervention-induced change will be assessed with an assessment session 6 weeks post-intervention. Mixed effect, repeated measure ANOVAS will be used to analyze intervention-induced change.

NCT ID: NCT03206996 Completed - Clinical trials for Autism Spectrum Disorder

Exposure Therapy for Auditory Sensitivity in Autism

Start date: September 30, 2017
Phase: N/A
Study type: Interventional

Auditory hyper-reactivity affects up to 66% of children with autism spectrum disorder (ASD) and has been linked to greater stress and anxiety for children and their families. Exposure and Response Prevention (E/RP) is highly effective for reducing obsessive/compulsive behaviors in children with both OCD and ASD. This study is the first to assess the feasibility and efficacy of E/RP for auditory sensory hyper-reactivity in ASD.

NCT ID: NCT03206437 Completed - Anxiety Disorders Clinical Trials

Effect of Mindfulness Meditation on Physiological Response to Unpredictable Stimuli

Start date: June 20, 2017
Phase: N/A
Study type: Interventional

This study will evaluate the effects of Mindfulness-Based Stress Reduction (MBSR) on physiological reactivity. This study will focus on individuals with anxiety who will participate in an 8-week MBSR class. The investigators will test participants' reactivity to both predictable and unpredictable stimuli before and after the class to understand the physiological changes that may occur after to the intervention. Secondary measures include psychometric instruments and a delay discounting task.

NCT ID: NCT03205839 Completed - Burns Clinical Trials

Acceptance-based Self-help for Individuals With Visible Difference and Social Anxiety

Start date: July 27, 2017
Phase: N/A
Study type: Interventional

The acceptance and commitment therapy (ACT) model theoretically fits with treating appearance-related anxiety in individuals with a visible difference. This study examines the effectiveness of an acceptance-based self-help manual for this population.

NCT ID: NCT03205423 Completed - Clinical trials for Alcohol Use Disorder

Medication Development for Opioid and Alcohol Abuse

Start date: August 1, 2017
Phase: Phase 2
Study type: Interventional

The present proposal will evaluate the ability of gabapentin maintenance to reduce the abuse liability of alcohol, oxycodone, and alcohol in combination with oxycodone in participants with both Opioid Use Disorder and Alcohol Use Disorder.

NCT ID: NCT03203707 Completed - Bipolar Disorder Clinical Trials

Early Assessment and Intervention for Adolescents at Risk for Bipolar Disorder

Start date: April 1, 2011
Phase: N/A
Study type: Interventional

Bipolar disorder is a severe and chronic illness associated with significant occupational and social impairment, enormous public health costs, and high rates of suicide. The single most potent risk factor for the development of bipolar disorder is a first-degree family member with the illness; indeed, offspring of parents with bipolar disorder are a particularly high-risk group who typically display early onset and severe course of illness. Thus, early assessment and intervention for the children of parents with bipolar disorder focused on specific, measurable, and modifiable risk factors has the potential to prevent or ameliorate the progression of bipolar disorder in those at highest risk.

NCT ID: NCT03203395 Completed - Depression Clinical Trials

Screening for Depression and Anxiety in Patients With Heart Disease

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

Depression is a risk factor for morbidity and mortality in patients with heart disease, and has a negative impact on quality of life, work capacity and treatment adherence. Screening for depression among heart patients are therefore recommended by the Norwegian Health Authorities. Also, symptoms of anxiety may negatively affect rehabilitation due to e.g. fear of physical activity and excessive worry. Patients currently receiving treatment for heart disease at Diakonhjemmet Hospital will be screened for symptoms of depression and anxiety. If such symptoms are detected, patients will be offered a counselling session with a clinical psychologist. Further, routines for collaborative communication between clinical psychologist, cardiologist and the patient's general physician will be emphasized.